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Abstract
Background: The Streptococcus anginosus group (SAG) play important roles in respiratory infections. It is ordinarily
difficult to distinguish them from contaminations as the causative pathogens of respiratory infections because they
are often cultured in respiratory specimens. Therefore, it is important to understand the clinical characteristics and
laboratory findings of respiratory infections caused by the SAG members. The aim of this study is to clarify the role
of the SAG bacteria in respiratory infections.
Methods: A total of 30 patients who were diagnosed with respiratory infections which were caused by the SAG
bacteria between January 2005 and February 2015 were retrospectively evaluated.
Results: Respiratory infections caused by the SAG were mostly seen in male patients with comorbid diseases and
were typically complicated with pleural effusion. Pleural effusion was observed in 22 (73.3%) patients. Empyema
was observed in half of the 22 patients with pleural effusion. S. intermedius, S. constellatus and S. anginosus were
detected in 16 (53.3 %), 11 (36.7 %) and 3 (10.0 %) patients, respectively. Six patients had mixed-infections. The
duration from the onset of symptoms to the hospital visit was significantly longer in “lung abscess” patients than
in “pneumonia” patients among the 24 patients with single infections, but not among the six patients with
mixed-infection. The peripheral white blood cell counts of the “pneumonia” patients were higher than those
of the “lung abscess” patients and S. intermedius was identified significantly more frequently in patients with
pulmonary and pleural infections (pneumonia and lung abscess) than in patients with bacterial pleurisy only.
In addition, the patients in whom S. intermedius was cultured were significantly older than those in whom
S. constellatus was cultured.
Conclusions: Respiratory infections caused by the SAG bacteria tended to be observed more frequently in male
patients with comorbid diseases and to more frequently involve purulent formation. In addition, S. intermedius
was mainly identified in elderly patients with having pulmonary infection complicated with pleural effusion,
and the aspiration of oral secretions may be a risk factor in the formation of empyema thoracis associated
with pneumonia due to S. intermedius.
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Background
The Streptococcus anginosus group (SAG), which is often
referred to as the Streptococcus milleri group, has been
widely detected in the mouth, the upper respiratory tract,
the gastrointestinal tract and the vagina [1]. At least three
different species have been classified into the SAG: S.
intermedius, S. constellatus and S. anginosus [2, 3].
The important roles of the streptococci in various
types of respiratory infections have recently been re-
ported [4–6]. We also reported, based on the results of a
clone library analysis of the 16S ribosomal RNA gene,
that the streptococci play important roles in the patho-
genesis of respiratory infections [7, 8]. Among the vari-
ous streptococci, the SAG bacteria have been reported
to be particularly important in the pathogenesis of re-
spiratory infections [1, 6, 9–12].
It has been reported, because of the unique character-
istics of the SAG bacteria, they tend to form abscesses
and empyema thoracis [3, 12, 13], and such SAG-based
infections account for 13–50 % of all cases of pulmonary
abscess and/or empyema thoracis [5, 9, 11, 14]. It is difficult
to determine whether they are the causative pathogens of
respiratory tract infections when the SAG bacteria are ob-
tained in sputum cultivation because the SAG bacteria are
resident members of the flora of both the oral and/or upper
respiratory tract. In addition to the culture results, it is
therefore important to understand the clinical characteris-
tics and the laboratory findings related to thoracic SAG
infection.
We herein retrospectively investigated the clinical
characteristics of respiratory infections caused by mem-
bers of the SAG.
Methods
Study design and patients
This retrospective study was conducted at the University
of Occupational and Environmental Health, Japan (UOEH)
and Wakamatsu Hospital of the UOEH. Patients with posi-
tive SAG bacteria cultures from specimens obtained from
the respiratory tract, pleural effusion, blood, and other
samples from January 2005 to February 2015 in the UOEH,
and from April 2011 to February 2015 in Wakamatsu
Hospital of UOEH (this hospital was established in April
2011) were enrolled in the present study. Patients were
singly enrolled in this study. This study was approved by
the Human and Animal Ethics Review Committee of the
UOEH (No. 26–229), and was in accordance with the
Declaration of Helsinki. The information that was collected
included the patients’ age, sex, comorbid diseases, clinical
manifestations and the laboratory and radiological findings.
Diagnostic criteria
Pneumonia was defined by the fulfillment of all three of
the following criteria: (1) positive findings for at least
one of the assessed clinical symptoms (fever, cough, spu-
tum production, chest pain); (2) the presence of new in-
filtrates without a cavity or low density areas on chest
radiography and/or computed tomography (CT); and (3)
positive findings for at least one of the sign(s) of
leukocytosis (a white blood cell count (WBC) of ≥
10,000/μl) and/or increased serum levels of C-reactive
protein (CRP). A lung abscess was defined when a cavity
or low density area within the infiltrates was confirmed
on chest radiography and/or CT in addition to the above
clinical criteria. Bacterial pleurisy, which is defined as
pleural infection due to bacteria, was macroscopically
defined by the existence of purulent pleural fluid or in-
flammatory cells (predominantly neutrophils) in the
pleural effusion in addition to (1) and (3) of the above
criteria. Pneumonia and lung abscess, with or without
pleural effusion, was described as “pneumonia” and
“lung abscess”, respectively, in spite of the associated
pleural effusion, while bacterial pleurisy without pneu-
monia or lung abscess was described as “bacterial pleur-
isy only”. Complicated parapneumonic effusion was
defined by a low glucose level (<40 mg/dL) and high
levels of lactate dehydrogenase (>1000 IU/L), or positive
gram staining or culture results. Empyema thoracis was
defined by the existence of macroscopically observable
purulent pleural fluid [15]. Patients who did not fulfill
the above-described diagnostic criteria (pneumonia, lung
abscess, and bacterial pleurisy only) were excluded from
the study.
Microbiological evaluation
Bacterial cultures were evaluated using a semi-quantitative
method [8]. As previously reported, the SAG bacteria were
indicated as causative pathogens in the present study by a
bacterial volume of “1+ (≥103–105 colony-forming units
(CFU)/ml)” in bronchoalveolar lavage fluid (BALF) or “2+
(≥106 CFU/ml)” in sputum samples by reference to the
results of quantitative culture, the findings of which in-
cluded ≥106 CFU/ml in sputum and 104 CFU/ml in BALF
[16–18]. The SAG bacteria were also identified as causa-
tive pathogens when blood or pleural effusion culture re-
sults were found to be positive. As previously described,
the isolated bacterial species were identified using a
VITEK 2 system (bio-Mérieux) with or without an API 20
STREP system (bio-Mérieux) [19]. Patients who did not
fulfill the following criteria were excluded to avoid bacter-
ial contamination to the extent that was possible, even
when one of the above diagnostic criteria for pneumonia,
lung abscess and bacterial pleurisy was fulfilled: a bacterial
volume of “≥1+” in BALF or “≥2+” in sputum samples.
Statistical analysis
After excluding the 6 patients with mixed infection to
clarify the characteristics of SAG respiratory infection,
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we analyzed the results of 24 patients. All statistical ana-
lyses were performed using the SPSS software package
(version 19), and a value of p < 0.05 was considered to be
statistically significant. Continuous variables were com-
pared using the Mann-Whitney (non-parametric) U-test,
while categorical variables were compared using Fisher’s
exact test (2 × 2), as appropriate.
Results
Patient characteristics and laboratory findings of 30
patients
Among the 944 patients in whom SAG bacteria were
cultured during the study period, 109 patients showed
cultures that were positive for SAG bacteria from
lower respiratory tract, pleural effusion or blood sam-
ples. In these 109 patients, 74 patients were excluded
because they did not fulfill the diagnostic criteria of
pneumonia, lung abscess or bacterial pleurisy only,
and 5 patients were excluded because their bacterial
volume, which was calculated semi-quantitatively, did
not fulfill the diagnostic criteria. Finally, a total of 30
patients were diagnosed with a respiratory infection
(pneumonia, lung abscess, bacterial pleurisy only) due
to S. intermedius, or S. constellatus, or S. anginosus
(Fig. 1). The clinical characteristics, laboratory find-
ings of the 30 patients are summarized in Table 1. The
average age was 68.9 ± 14.2 years, and 22 (73.3 %) of
the 30 patients were male. Most of the patients (28/30,
93.3 %) had at least one comorbid illness. Pleural effu-
sion was observed in 22 of the 30 patients, and pleural
effusion was evaluated in 21 of 22 patients. The
amount of pleural effusion in the remaining patient,
who had a lung abscess, was too small to evaluate.
Complicated pleural effusion and empyema were found in
10 (47.6 %) and 11 (52.4 %) patients, respectively (among
the 21 patients in whom pleural effusion was examined).
The numbers of patients with “pneumonia”, “lung abscess”
and “bacterial pleurisy only” were 19 (63.3 %), 5 (16.7 %),
6 (20.0 %), respectively.
Clinical outcomes
The antimicrobial treatment regimens and outcomes are
summarized in Table 1. Antibiotic monotherapy was ad-
ministered to 25 of 30 (83.3 %) patients, and 19 of 25
(63.3 %) patients were treated with carbapenems. Clinda-
mycin was concomitantly used in combination with
beta-lactam and quinolone antibiotics in 4 of the 5
(80.0 %) patients treated with combined therapy. Eleven
(36.6 %) patients were treated with antibiotics only,
while surgical treatments were applied (in addition to
antibiotic therapy) in 19 (63.3 %) patients (Table 1).
There were no significant differences in the lengths of
stay or the treatment responses among the patients diag-
nosed with any of the three diseases. Six patients
(20.0 %) were admitted to the intensive care unit (ICU)
and there were two cases (6.7 %) of in-hospital
mortality.
Microbiology
S. intermedius, S. constellatus, and S. anginosus were
detected in 16 (53.3 %), 11 (36.7 %), and 3 (10.0 %),
patients, respectively (Table 2). Mixed infections with
non-SAG bacteria were observed in 6 of 30 (20.0 %) pa-
tients (pneumonia; 3, lung abscess; 0, bacterial pleurisy
only; 3), with mixed infections with anaerobic pathogens
accounting for 3 of 30 (10.0 %) cases (Table 2).
The clinical features, laboratory features, treatment, and
outcomes among the patients with single infections
After excluding the six patients with mixed infections, 16,
5, and 3 patients were classified as having “pneumonia”,
“lung abscess” and “bacterial pleurisy only”, respectively
(Table 3). No significant differences were observed among
three diseases with regard to age, gender, comorbid
Fig. 1 A flow diagram of the patient inclusion and exclusion criteria
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diseases and symptoms at presentation. The duration
(in days) from the onset of symptoms to the patient’s
hospital visit was significantly longer in the “lung ab-
scess” patients than in the “pneumonia” patients. The
“pneumonia” patients showed higher peripheral WBC
counts than the “lung abscess” patients. No significant
differences were observed in the numbers of detected
bacteria, the treatments or the clinical outcomes of
these three categories (Table 4).
The clinical and laboratory features in patients with
pleural effusion
The clinical characteristics and laboratory findings of the
“pneumonia” or “lung abscess” patients that were compli-
cated with pleural effusion and the “bacterial pleurisy
Table 1 The clinical and laboratory features of 30 patients with
Streptococcus anginosus group infections
Total (n = 30)
Age (y); mean ± SD 68.9 ± 14.2
Gender (male/female) 22/8
BMI; mean ± SD 20.1 ± 4.1
Comorbidity diseases 28 (93.3)
Neoplastic disease 8 (26.7)
Cerebrovascular disease 12 (40.0)
Chronic pulmonary disease 3 (10.0)
Chronic cardiac disease 4 (13.3)
Chronic liver disease 3 (10.0)
Chronic renal disease 4 (13.3)
Diabetes mellitus 6 (20.0)
Smoking history 13 (43.3)
Alcohol 8 (26.7)





Blood sputum 2 (6.7)
Chest pain 14 (46.7)
Disturbance of consciousness 3 (10.0)
Previous antibiotic treatment 8 (26.7)
Clinical parameter
Body temperature (°C) 37.8 ± 0.7
Systolic blood pressure (mmHg) 118.8 ± 20.9
Heart rate (beats/min) 103.7 ± 17.0
Respiratory rate (/min) 23.3 ± 5.7
Hypoxia (SpO2≤ 90 %) 18 (60.0)
Laboratory findings
White blood cell counts (/μL) 17,627 ± 10,008
C-reactive protein (mg/dL) 18.0 ± 11.1
Albumin (g/dL) 2.5 ± 0.6
Pleural effusion 22 (73.3)
Complicated pleural effusion 10 (33.3)
Empyema 11 (36.7)
Cultured bacteria
SAG only 24 (80.0)
Mixed infection 6 (20.0)
Pneumonia severity index 120.8 ± 42.2
Antibiotic treatment
Monotherapy 25 (83.3)
Penicillin/beta-lactamase inhibitors 3 (10.0)
Carbapenem 19 (63.3)
Table 1 The clinical and laboratory features of 30 patients with
Streptococcus anginosus group infections (Continued)
Linezolid 1 (3.3)
Macrolide 2 (6.7)
Combination therapy 5 (16.7)
3th-cephem +Macrolide 1 (3.3)
4th-cephem + Clindamycin 1 (3.3)
Carbapenem + Clindamycin 2 (6.7)
Fluoroquinolone + Clindamycin 1 (3.3)
Additional treatment
Only drainage 5 (16.7)
Drainage + lung decortication 14 (46.7)
Length of stay (days) 27.7 ± 18.8
ICU admission 6 (20.0)
In-hospital mortality 2 (6.7)
SD standard deviation, BMI body mass index, SpO2 pulse oximetric saturation,
SAG streptococcus anginosus group, ICU intensive care unit
Table 2 The bacteria isolated from 30 patients with Streptococcus
anginosus group infections
Cultured bacteria No (%)
S. intermedius 16 (53.3)
S. intermedius only 14 (46.7)
S. intermedius + H. influenzae 1 (3.3)
S. intermedius + Fusobacterium spp. 1 (3.3)
S. constellatus 11 (36.7)
S. constellatus only 8 (26.7)
S. constellatus + E. coli 1 (3.3)
S. constellatus + K. pneumoniae 1 (3.3)
S. constellatus + Bacteroides spp. + Peptostreptococcus spp. 1 (3.3)
S. anginosus 3 (10.0)
S. anginosus only 2 (6.7)
S. anginosus + Bacteroides spp. 1 (3.3)
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Table 3 The clinical and laboratory features of 24 patients which was classified in pneumonia, lung abscess and bacterial pleurisy
only
Total Pneumonia Lung abscess Bacterial pleurisy only p-Value
(n = 24) (n = 16) (n = 5) (n = 3)
Age (y); mean ± SD 72.1 ± 11.6 74.8 ± 9.8 68.0 ± 15.4 65.0 ± 9.8 NS
Gender (male/female) 18/6 11/5 5/0 2/1 NS
BMI; mean ± SD 20.3 ± 4.4 19.6 ± 4.6 25.0 ± 3.5 19.6 ± 2.2 p = 0.032**
Comorbidity diseases 23 (95.8) 16 (100) 4 (80.0) 3 (100) NS
Neoplastic disease 7 (29.2) 4 (25.0) 2 (40.0) 1 (33.3) NS
Cerebrovascular disease 9 (37.5) 7 (43.8) 1 (20.0) 1 (33.3) NS
Chronic pulmonary disease 2 (8.3) 1 (6.3) 1 (20.0) 0 (0.0) NS
Chronic cardiac disease 4 (16.7) 4 (25.0) 0 (0.0) 0 (0.0) NS
Chronic liver disease 3 (12.5) 3 (18.8) 0 (0.0) 0 (0.0) NS
Chronic renal disease 4 (16.7) 2 (12.5) 0 (0.0) 2 (66.7) NS
Diabetes mellitus 6 (25.0) 4 (25.0) 0 (0.0) 2 (66.7) NS
Smoking history 10 (41.7) 7 (43.8) 3 (60.0) 0 (0.0) NS
Alcohol 6 (25.0) 5 (31.3) 1 (20.0) 0 (0.0) NS
The days from symptom onset to consultation (days) 16.0 ± 19.6 9.0 ± 9.3 38.6 ± 30.8 16.0 ± 14.8 p = 0.031*
Symptoms at presentation
Fever 19 (79.2) 13 (81.3) 4 (80.0) 2 (66.7) NS
Cough 12 (50.0) 7 (43.8) 4 (80.0) 1 (33.3) NS
Sputum 12 (50.0) 7 (43.8) 4 (80.0) 1 (33.3) NS
Blood sputum 2 (8.3) 0 (0.0) 1 (20.0) 1 (33.3) NS
Chest pain 12 (50.0) 9 (56.3) 1 (20.0) 2 (66.7) NS
Disturbance of consciousness 3 (12.5) 3 (18.8) 0 (0.0) 0 (0.0) NS
Previous antibiotic treatment 7 (29.2) 6 (37.5) 0 (0.0) 1 (33.3) NS
Clinical parameter
Body temperature (°C) 37.8 ± 0.80 37.9 ± 0.81 37.5 ± 0.97 37.8 ± 0.59 NS
Systolic blood pressure (mmHg) 120.0 ± 22.2 117.8 ± 22.4 116.4 ± 19.3 135.3 ± 27.2 NS
Heart rate (beats/min) 100.6 ± 15.1 102.7 ± 16.7 93.6 ± 13.4 101.0 ± 3.6 NS
Respiratory rate (/min) 23.5 ± 6.1 25.0 ± 5.5 17.3 ± 5.1 27.0 ± 4.2 p = 0.029*
Hypoxia (SpO2≤ 90 %) 15 (62.5) 12 (75.0) 1 (20.0) 2 (66.7) p = 0.047
*
Laboratory findings
White blood cell counts (/μL) 16,763 ± 9412 18,869 ± 9532 10,080 ± 2906 16,667 ± 13,164 p = 0.014*
C-reactive protein (mg/dL) 18.2 ± 10.5 19.2 ± 11.0 11.7 ± 7.1 24.1 ± 9.6 NS
Albumin (g/dL) 2.5 ± 0.6 2.5 ± 0.7 2.7 ± 0.7 2.2 ± 0.4 NS
Pleural effusion 19 (79.2) 14 (87.5) 2 (40.0) 3 (100) NS
Complicated pleural effusion 9 (37.5) 6 (37.5) 1 (20.0) 2 (66.7) NS
Empyema 9 (37.5) 8 (50.0) 0 (0.0) 1 (33.3) NS
Cultured bacteria
S. intermedius 14 (58.3) 11 (68.8) 3 (60.0) 0 (0.0) NS
S. constellatus 8 (33.3) 4 (25.0) 2 (40.0) 2 (66.7) NS
S. anginosus 2 (8.3) 1 (6.3) 0 (0.0) 1 (33.3) NS
Pneumonia severity index 125.2 ± 37.3 128.1 ± 37.8 123.6 ± 48.6 112.0 ± 16.5 NS
SD standard deviation, BMI body mass index, SpO2 pulse oximetric saturation, NS not significant
*Statistically significant difference in the comparison between pneumonia and lung abscess; **Statistically significant difference in the comparison between
pneumonia and bacterial pleurisy
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only” patients are shown in Additional file 1: Table S1.
There were no significant differences in age, gender, co-
morbid diseases, symptoms at presentation, and clinical
and laboratory parameters between these two categories.
Whereas. S. intermedius was significantly more frequently
identified in “pneumonia” and “lung abscess” patients with
“pleural effusion” than in patients with “bacterial pleurisy
only” (Fig. 2).
The clinical and laboratory features of the different
species of SAG
There were no significant differences in the comorbid
diseases, symptoms at presentation, laboratory findings,
treatments or outcomes among three SAG bacterial spe-
cies (Additional file 1: Table S2). The patients with posi-
tive S. intermedius cultures were significantly older than
those with positive S. constellatus cultures (Fig. 3a). All
Table 4 The treatments and outcomes of 24 patients which was classified in pneumonia, lung abscess and bacterial pleurisy only
Total Pneumonia Lung abscess Bacterial pleurisy only p-Value
(n = 24) (n = 16) (n = 5) (n = 3)
Monotherapy 20 (83.3) 12 (75.0) 5 (100) 3 (100) NS
Penicillin/beta-lactamase inhibitors 1 (4.2) 1 (6.3) 0 (0.0) 0 (0.0) NS
Carbapenem 17 (70.8) 10 (62.5) 4 (80.0) 3 (100) NS
Linezolid 1 (4.2) 0 (0.0) 1 (20.0) 0 (0.0) NS
Macrolide 1 (4.2) 1 (6.3) 0 (0.0) 0 (0.0) NS
Combination therapy 4 (16.7) 4 (25.0) 0 (0.0) 0 (0.0) NS
4th-cephem + Clindamycin 1 (4.2) 1 (6.3) 0 (0.0) 0 (0.0) NS
Carbapenem + Clindamycin 2 (8.3) 2 (12.5) 0 (0.0) 0 (0.0) NS
Fluoroquinolone + Clindamycin 1 (4.2) 1 (6.3) 0 (0.0) 0 (0.0) NS
Additional treatment 16 (66.7) 12 (75.0) 1 (20.0) 3 (100) NS
Only drainage 4 (16.7) 2 (12.5) 1 (20.0) 1 (33.3) NS
Drainage + lung decortication 12 (50.0) 10 (62.5) 0 (0.0) 2 (66.7) NS
Length of stay (days) 29.3 ± 19.7 31.4 ± 20.9 28.6 ± 21.0 19.0 ± 9.5 NS
ICU admission 6 (25.0) 6 (37.5) 0 (0.0) 0 (0.0) NS
In hospital mortality 2 (8.3) 2 (12.5) 0 (0.0) 0 (0.0) NS
NS not significant, ICU intensive care unit
Fig. 2 The differences in the detection rates of the three bacterial species in the pneumonia and lung abscess patients with pleural effusion
(n = 16) and those with bacterial pleurisy only (n = 3). a Streptococcus intermedius, b Streptococcus constellatus, c Streptococcus anginosus
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of the eight patients in whom S. constellatus was identi-
fied were males, and significantly more male patients
were included among the patients with S. constellatus
than those with S. anginosus (Fig. 3b).
Discussion
The SAG bacteria include some of the important patho-
gens in respiratory infections. In the present study, we
evaluated the clinical characteristics of respiratory infec-
tions caused by the SAG members using culture methods,
and showed that the patients tended to be males with
comorbid diseases, and that their condition tended to be
complicated with pleural effusion with purulent forma-
tion. In addition, S. intermedius infections were mainly
identified in older patients with pulmonary infections
complicated with pleural effusion. Therefore, we also
found that the aspiration of oral secretions may be a risk
factor for the formation of empyema thoracis associated
with pulmonary infection due to S. intermedius.
The SAG bacteria are fascultative anaerobic pathogens
that ordinarily colonize the mouth and the upper
respiratory tract. In this study, only 11 of 72 (15.3 %) pa-
tients were diagnosed with respiratory infections caused
by SAG bacteria according to the cultivation results of
lower respiratory tract specimens. The diagnosis of
resiratory infections caused by SAG was made mainly
based on the detection of SAG from pleural effusion,
and three of these 11 patients showed the same bacterial
species in both lower respiratory tract samples and
pleural effusion. On the other hand, pneumonia without
pleural effusion caused by SAG was only observed in 5
of 30 (16.7 %) patients with a SAG infection. This find-
ing was in line with a similar report, which showed a
low SAG detection rate in patients with pneumonia
without pleural effusion [11]. In consideration of the
above findings, a relatively small number of patients
seems to have received a precise diagnosis of a respira-
tory infection caused by SAG using only lower respira-
tory specimens. Physicians therefore need to exercise
caution, and consider their patient’s clinical background
in the diagnosis of respiratory infections caused by SAG
bacteria even if the SAG bacteria are cultured in samples
obtained from the lower respiratory tract.
Previous reports have demonstrated that SAG infec-
tions occur mainly in male patients, patients with
comorbid diseases, and pus formation, and that the
mean time to pus formation is 18 days [1, 10, 20]. Simi-
lar clinical characteristics were observed in the present
study. In this study, patients with pneumonia, with or
without pleural effusion, tended to show a shorter
period from the onset of symptoms to the diagnosis
and more elevated levels of peripheral WBC counts
than patients with lung abscess.
Pleural effusion was observed in 73.3 % of the patients
and many of them fulfilled the diagnosis for complicated
pleural effusion or empyema. Okada et al. reported that
pleural effusion was observed in 54.5 % of patients with
SAG infections, and that pleural effusion was more
frequently observed in patients with SAG infections than
in patients were infected with other pathogens, including
S. pneumoniae, and they therefore speculated that re-
spiratory infections caused by SAG should be especially
considered in patients with pleural effusion [21]. In rela-
tion to medical treatments, early surgical treatment was
necessary in 20 of 30 (66.7 %) patients. The application
of early surgical treatment, in addition to appropriate
antibiotic use for patients with thoracic infections caused
by SAG, was associated with a low mortality rate [10], a
Fig. 3 An age and gender-based comparison of each bacterial member of the Streptococcus anginosus group. a age, b gender
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shortened length of hospital stay and an increase in the
number of patients who could be discharged to their
homes [22]. The mortality rate in this study was low
(6.7 %), and 19 of 30 (63.3 %) patients were treated with
additional surgical treatments in combination with anti-
biotic treatment. Thus it should be considered that early
(additional) surgical intervention might lead to favorable
outcome in patients with respiratory infections caused by
SAG.
Previous reports of the three different members of the
SAG (S. intermedius, S. constellatus and S. anginosus)
described that the bacteria were observed equally in
thoracic infections and that there were no significant dif-
ferences among these three pathogens [20, 22]. S. inter-
medius is commonly isolated from the brain or the liver,
while S. constellatus and S. anginosus are widely distrib-
uted and can be found in infections of the respiratory
tract or blood [2, 3]. On the other hand, higher rates of
S. intermedius detection have also been reported from
respiratory sources [23]. In addition, S. intermedius and
S. constellatus are generally more frequently associated
with abscess formation than S. anginosus [24, 25]. In this
study, S. intermedius and S. constellatus were mainly
detected in patients with respiratory infections. Interest-
ingly, S. intermedius was significantly more common in
patients with “pneumonia or lung abscess with pleural
effusion” than those with “bacterial pleurisy only”, and S.
intermedius also tended to be more frequently detected
in older patients. Several mechanisms for these thoracic in-
fections caused by SAG have been suggested, including the
aspiration of oral secretions, direct implantation by trauma
or surgery, extension by contiguity, and hematogenous
dissemination [26]. Teramoto et al. reported that aspir-
ation often contributes to the pathogenesis of pneumonia
in elderly patients, especially those over 70–80 years of
age, and an increased age is associated with the risk of de-
veloping aspiration pneumonia [27]. Therefore, the aspir-
ation of oral secretions may be able to cause lung infection
with empyema due to S. intermedius in older patients. In
comparison with the two other SAG members, S. con-
stellatus tended to be more frequently detected in
male patients in this study, although there were no
significant differences in the gender of patients whose
cultures were positive for S. intermedius or S. constel-
latus. This finding is contrary to previous reports
which demonstrated that there were no gender differ-
ences in the rate patients infected with these three
pathogens [23]. The reasons for the gender differ-
ences between the three SAG members remain to be
elucidated and further investigation is necessary.
The reported rates of mixed infections involving bac-
terial species other than SAG range from 13 to 45 % in
patients with respiratory infections caused by the SAG
bacteria [10, 12, 21, 26]. The reported rates of mixed
infections involving the SAG bacteria combined with an-
aerobes range from 14 to 24 % [1, 5]. Anaerobes are
common pathogens in mixed infections caused by the
SAG bacteria; the presence of anaerobes has been re-
ported to positively enhance SAG infection [9, 28]. In
the present study, mixed infections of SAG bacteria and
other bacterial species were observed in 20 % of the pa-
tients, while mixed infections of SAG bacteria and anaer-
obes were observed in 10 % of patients. We previously
reported the clinical significance of anaerobic bacteria in
bacterial pneumonia [7, 8] and pleurisy [15], and demon-
strated that anaerobic pathogens may be underestimated
by current culture methods [7, 8, 15]. Further studies are
necessary to elucidate the clinical and pathogenic roles of
the anaerobic pathogens in mixed infections involving the
SAG bacteria.
The present study is associated with several limita-
tions. First, this study was retrospective in nature and in-
volved a relatively small sample size. Second, it was
unclear whether the appropriate conditions were created
for the detection of anaerobic cultures. Third, although
quantitative culture methods are desirable in the bac-
teriological and etiological evaluation of pneumonia, we
were only able to evaluate the bacterial composition
semi-quantitatively.
Conclusion
We summarized the clinical characteristics of patients
with respiratory infections induced by the SAG bac-
teria, and found that the respiratory infections tended
to more frequently occur in males with comorbid dis-
eases and involve pleural effusion with purulent for-
mation. S. intermedius was mainly identified in elderly
patients with lung infection complicated with pleural
effusion, and aspiration of the oral secretions may be a
risk factor in the formation of empyema thoracis asso-
ciated with pneumonia due to S. intermedius. In
addition to investigating culture results, physicians
should pay more attention to the clinical background,
including symptoms such as pleural effusion.
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